A Double-Blind, Randomized, Placebo-Controlled Trial of Augmentation With Lamotrigine or Placebo in Patients Concomitantly Treated With Fluoxetine for Resistant Major Depressive Episodes
The DOI matches its Crossref record.
Abstract
BACKGROUND: Evidence of the antidepressant efficacy of lamotrigine is increasing, although there are no placebo-controlled trials of lamotrigine augmentation in depression. The aim of this study was to assess if augmentation with lamotrigine was superior to placebo in patients who were receiving fluoxetine for resistant major depressive episodes. METHOD: Twenty-three patients who had experienced at least 1 major depressive episode that was resistant to at least 1 prior trial of antidepressant therapy were selected. These patients were treated with fluoxetine, 20 mg/day, and concomitantly randomly assigned to receive either lamotrigine (N = 13) or placebo (N = 10) for 6 weeks. The dose of lamotrigine was titrated upward from 25 mg/day to 100 mg/day. Patients suffering from bipolar II disorder (N = 8) or from major depressive disorder (N = 15) (DSM-IV criteria) were enrolled, resulting in heterogeneity of the sample. The primary outcome measure was Hamilton Rating Scale for Depression score. Data were collected from 2000-2001. RESULTS: Lamotrigine was statistically superior to placebo on the Clinical Global Impressions scale at endpoint, both in absolute terms (mean +/- SD Clinical Global Impressions-Severity of Illness scores: lamotrigine, 2.15 +/- 1.28; placebo, 3.40 +/- 1.17; p =.0308) and using a responder analysis, with response defined as a Clinical Global Impressions-Improvement score of 2 or less (lamotrigine, 84.62% [N = 11]; placebo, 30.00% [N = 3]; p =.013). The effect of lamotrigine on Clinical Global Impressions scale scores was seen in both major depressive disorder and bipolar II disorder. Lamotrigine, however, failed to separate statistically from placebo on the Hamilton Rating Scale for Depression and Montgomery-Asberg Depression Rating Scale. This failure to differentiate on a primary outcome measure is essentially a negative study result. This result is most likely an artifact of the small sample size used and the resultant limited power of the study. CONCLUSION: The results of this trial add to the literature suggesting potential efficacy of the antidepressant profile of lamotrigine. In addition, this study points to a possible role of lamotrigine as an augmentation agent in depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two studies (Barbosa et al., 2003; Carpenter et al., 2002) had included patients with MDD (n=38) and bipolar-II disorder (n=11), without providing separate outcomes for MDD patients.”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Barbosa et al., 2003
Citations
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,520
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“40%, NNT 3) (Barbosa et al., 2003), and a randomised open comparison with lithium found a non-significantly better response to lamotrigine (53% vs.”
BackgroundMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
(2007) · PubMed · Cited by 453
The Medical Management of Depression
Mann, J. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050730 · Cited by 421
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
“In an RCT that included eight patients with bipolar II depression, lamotrigine as add-on to the antidepressant fluoxetine, demonstrated some efficacy compared with placebo on measures of global improvement, but not on measures of depression (630).”
BackgroundBeyond Monoamines: Glutamatergic Function in Mood Disorders
Kugaya, A., & Sanacora, G. (2005) · CNS Spectrums · doi:10.1017/s1092852900010403 · Cited by 290
Berlim, M. T., & Turecki, G. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.03.009 · Cited by 249
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Therapeutic Options for Treatment-Resistant Depression
Shelton, R. C., Osuntokun, O., Heinloth, A. N., & Corya, S. A. (2010) · CNS Drugs · doi:10.2165/11530280-000000000-00000 · Cited by 205
Penn, E., & Tracy, D. K. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312445469 · Cited by 200
“Pharmacological treatment is often by augmentation therapy where a mood stabiliser (such as lithium or lamotrigine) or an antipsychotic (such as olanzapine, quetiapine or risperidone) is added to an existing antidepressant [Carpenter et al. 2002; Barbosa et al. 2003].”
BackgroundPsychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy
Weintraub, D., Buchsbaum, R., Resor, S. R., & Hirsch, L. J. (2007) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2006.08.008 · Cited by 187
“The low rates of PSEs associated with LTG and GBP are well-documented [2,6–8], and LTG is currently indicated for use in maintenance treatment of bipolar I disorder [12,13].”
BackgroundSerotonin transporter gene hypomethylation predicts impaired antidepressant treatment response
Domschke, K., Tidow, N., Schwarte, K., Deckert, J., Lesch, K.-P., Arolt, V., Zwanzger, P., & Baune, B. T. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571400039x · Cited by 178
Predictors of Lamotrigine‐associated Rash
Hirsch, L. J., Weintraub, D. B., Buchsbaum, R., Spencer, H. T., Straka, T., Hager, M., & Resor, S. R. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00423.x · Cited by 164
“LTG also is indicated for maintenance treatment of bipolar I disorder, and evidence exists that LTG is effective in the treatment of absence and primary generalized tonic–clonic seizures (2–4), neuropathic pain (5), and depression (6).”
BackgroundFava, M., & Rush, A. J. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000091771 · Cited by 151
Pharmacological Treatments for Patients with Treatment-Resistant Depression
Ruberto, V. L., Jha, M. K., & Murrough, J. W. (2020) · Pharmaceuticals · doi:10.3390/ph13060116 · Cited by 147
“A double-blind study by Fedgchin et al. found that intranasal esketamine in a dose of 84 mg (n = 114) did not cause a significantly greater decrease in MADRS score compared to a placebo (n = 113) in a sample of participants who failed to respond to at least two antidepressants (p = 0.088).”
BackgroundInfluentialBipolar II Disorder: Epidemiology, Diagnosis and Management
Benazzi, F. (2007) · CNS Drugs · doi:10.2165/00023210-200721090-00003 · Cited by 179
Psychotropic effects of antiepileptic drugs
Ettinger, A. B. (2006) · Neurology · doi:10.1212/01.wnl.0000247045.85646.c0 · Cited by 154
Papakostas, G. I. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133su1c.03 · Cited by 143
Berk, M., & Dodd, S. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2004.00152.x · Cited by 134
Self-citationPoureshghi, F., Ghandforoushan, P., Safarnejad, A., & Soltani, S. (2016) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2016.09.046 · Cited by 131
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Self-citationEvidence-based pharmacotherapy of treatment-resistant unipolar depression
Dold, M., & Kasper, S. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1248852 · Cited by 118
“Add-on treatment with lamotrigine did not significantly differ from placebo augmentation in 3 double-blind RCTs (Barbosa et al. 2003; Santos et al. 2008; Barbee et al. 2011).”
BackgroundAntiepileptic drugs and adverse skin reactions: An update
Błaszczyk, B., Lasoń, W., & Czuczwar, S. J. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.11.009 · Cited by 126
Carvalho, A. F., Cavalcante, J. L., Castelo, M. S., & Lima, M. C. O. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00846.x · Cited by 110
“Recently, however, lamotrigine (100–300 mg ⁄ day) has been tested for this effect as in depression resistant to either paroxetine (125) or fluoxetine (126).”
BackgroundCorrelating lamotrigine serum concentrations with tolerability in patients with epilepsy
Hirsch, L. J., Weintraub, D. B., Du, Y., Buchsbaum, R., Spencer, H. T., Hager, M., Straka, T., Bazil, C. W., Adams, D. J., Resor, S. R., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000138424.33979.0c · Cited by 104
Therapeutic options in treatment-resistant depression
Vieta, E., & Colom, F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.583675 · Cited by 102
Sartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B., Brand, U., Fleischhacker, W., Goodwin, G., Grunze, H., Knapp, M., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 98
A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression
Suppes, T., Marangell, L. B., Bernstein, I. H., Kelly, D. I., Fischer, E. G., Zboyan, H. A., Snow, D. E., Martinez, M., Al Jurdi, R., Shivakumar, G., et al. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.02.004 · Cited by 96
“Two additional small double blind studies also support a potential role for LTG in the treatment of BDII depression (Schaffer et al, 2006; Barbosa et al, 2003).”
Novel glutamatergic drugs for the treatment of mood disorders
Murrough, J., Lapidus, K., & Soleimani, L. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36689 · Cited by 92
Treatment of bipolar depression: An update
Fountoulakis, K. Ν., Grunze, H., Panagiotidis, P., & Kaprinis, G. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.10.016 · Cited by 93
Augmentation strategies for treatment-resistant depression
Carvalho, A. F., Machado, J. R., & Cavalcante, J. L. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32831be9ef · Cited by 78
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
The hidden third: improving outcome in treatment-resistant depression
Schlaepfer, T. E., Ågren, H., Monteleone, P., Gasto, C., Pitchot, W., Rouillon, F., Nutt, D. J., & Kasper, S. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431748 · Cited by 74
“A certain degree of success has been observed with the augmentation of antidepressant therapy with lamotrigine in patients with TRD in a number of studies, including two open-label trials and one placebo-controlled trial (Barbosa et al., 2003; Gabriel, 2006; Schindler and Anghelescu, 2007).”
ResultKaster, M. P., Raupp, I. M., Binfaré, R. W., Andreatini, R., & Rodrigues, A. L. S. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.03.003 · Cited by 75
Caldiroli, A., Capuzzi, E., Tagliabue, I., Capellazzi, M., Marcatili, M., Mucci, F., Colmegna, F., Clerici, M., Buoli, M., & Dakanalis, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313070 · Cited by 70
“In a first double-blind RCT, conducted on 23 TRD patients, lamotrigine failed to significantly reduce both HAM-D and MADRS scores with respect to a placebo [81].”
BackgroundPharmacologic approaches to treatment resistant depression: a re-examination for the modern era
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003614781 · Cited by 70
“However, at least two small, placebo-controlled trials have found no difference in TRD response rates to lamotrigine augmentation [104], although the titration schedule in the second study meant that therapeutic doses of lamotrigine were maintained for less than 3 weeks [105].”
BackgroundManagement of bipolar depression with lamotrigine: an antiepileptic mood stabilizer
Prabhavalkar, K. S., Poovanpallil, N. B., & Bhatt, L. K. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00242 · Cited by 70
“Pilot studies have reported the augmentation therapy of lamotrigine with SSRI’s (fluoxetine and paroxetine) to be well tolerated and far more superior in efficacy than that of SSRI monotherapy (Normann et al., 2002; Barbosa et al., 2003).”
BackgroundAnticonvulsants in the Treatment of Major Depressive Disorder: An Overview
Vigo, D. V., & Baldessarini, R. J. (2009) · Harvard Review of Psychiatry · doi:10.1080/10673220903129814 · Cited by 69
What Happened to Lithium? Antidepressant Augmentation in Clinical Settings
Valenstein, M., McCarthy, J. F., Austin, K. L., Greden, J. F., Young, E. A., & Blow, F. C. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1219 · Cited by 69
Pharmacotherapy of bipolar mixed states
Krüger, S., Trevor Young, L., & Bräunig, P. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00197.x · Cited by 68
Solmi, M., Veronese, N., Zaninotto, L., van der Loos, M. L. M., Gao, K., Schaffer, A., Reis, C., Normann, C., Anghelescu, I.-G., & Correll, C. U. (2016) · CNS Spectrums · doi:10.1017/s1092852916000523 · Cited by 69
Schindler, F., & Anghelescu, I. G. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328014823d · Cited by 65
“In cases of treatment-resistant depression (TRD), guidelines usually recommend a combination or augmentation strategy (Bauer et al., 2002).”
BackgroundResultInfluentialGoforth, H. W., & Holsinger, T. (2007) · The Journal of ECT · doi:10.1097/01.yct.0000263257.44539.23 · Cited by 63
“In addition, lamotrigine and riluzole have antidepressant properties demonstrated in treatment-resistant cases of depression including bipolar depression.(14,15) Zarate et al(4) have noted that diverse studies indicative of glutamatergic dysfunction support a role in the pathophysiology of depression; and Sanacora et…”
BackgroundA critical review of pharmacotherapy for major depressive disorder.
Dupuy, J. M., Ostacher, M. J., Huffman, J., Perlis, R. H., & Nierenberg, A. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000083 · Cited by 61
The effectiveness of anticonvulsants in psychiatric disorders
Grunze, H. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.1/hcrgrunze · Cited by 67
Consoni, F. T., Vital, M. A. B. F., & Andreatini, R. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.01.003 · Cited by 59
“, 2000; Bowden, 2002; Barbosa et al., European Neuropsychopharmacology (2006) 16, 451—458”
Santos, M. A., Rocha, F. L., & Hara, C. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0302 · Cited by 51
Combination/augmentation strategies for improving the treatment of depression
Moret, C. (2005) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a798 · Cited by 70
“…such as valproate, carbamazepine (see review of Dietrich and Emrich 1998), and lamotrigine (randomized, double-blind, placebo-controlled study, Barbosa et al 2003), combined with classical antidepressants appear to be well tolerated and effective in treatment-resistant depressed patients.”
Lamotrigine in epilepsy, pregnancy and psychiatry – a drug for all seasons?
Vajda, F. J. E., Dodd, S., & Horgan, D. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.05.024 · Cited by 52
A review of acute treatments for bipolar depression
Silverstone, P. H., & Silverstone, T. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200405000-00001 · Cited by 55
“, 2002) although, in another smaller study, it did was no different to placebo (Barbosa et al., 2003).”
BackgroundResultNMDA antagonists under investigation for the treatment of major depressive disorder
Pochwat, B., Pałucha-Poniewiera, A., Szewczyk, B., Pilc, A., & Nowak, G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918951 · Cited by 47
“However, on the other hand, numerous randomized controlled trials call into question the utility of lamotrigine in the treatment of unipolar depression [91-94].”
BackgroundAbelaira, H. M., Réus, G. Z., Ribeiro, K. F., Zappellini, G., Ferreira, G. K., Gomes, L. M., Carvalho‐Silva, M., Luciano, T. F., Marques, S. D. O., STRECK, E. L., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.10.007 · Cited by 49
“Lamotrigine is an anticonvulsant drug that has shown efficacy in the treatment of bipolar depression and resistant major depressive episodes (Bowden et al., 1999; Calabrese et al., 1999; Frye et al., 2000; Barbosa et al., 2003).”
Evidence for the activity of lamotrigine at 5-HT1A receptors in the mouse forced swimming test
Bourin, M., Massé, F., & Hascoët, M. (2005) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0537 · Cited by 47
Besag, F., Vasey, M. J., Sharma, A., & Lam, I. C. H. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211045870 · Cited by 62
Ostadhadi, S., Ahangari, M. M., Nikoui, V., Norouzi‐Javidan, A., Zolfaghari, S., Jazaeri, F., Chamanara, M., Akbarian, R., & Dehpour, A. R. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.05.035 · Cited by 45
Lamotrigine Augmentation Strategy for Patients with Treatment-Resistant Depression
Gutierrez, R., McKercher, R. M., Galea, J., & Jamison, K. L. (2005) · CNS Spectrums · doi:10.1017/s1092852900010324 · Cited by 41
Barowsky, J., & Schwartz, T. L. (2006) · PubMed Central · Cited by 46
Target screening of chemicals of concern in recycled water
Busetti, F., Ruff, M., & Linge, K. L. (2015) · Environmental Science Water Research & Technology · doi:10.1039/c4ew00104d · Cited by 46
Brunoni, A. R., Tadini, L., & Fregni, F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009479 · Cited by 39
“). Some examples of the 35 trials classified as “dubious” were: a lamotrigine vs. placebo trial that concluded the active drug “is associated with superior efficacy” although this was true for some but not all analyses”
BackgroundSingle centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions
Błaszczyk, B., Szpringer, M., Czuczwar, S. J., & Lasoń, W. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71015-6 · Cited by 41
“parable to that of older aromatic AEDs is not known [7, 17, 18, 44, 71, 77, 78, 81, 99, 105, 107].”
BackgroundSystematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD)
Thomas, S. P., Nandhra, H. S., & Jayaraman, A. (2010) · Journal of Mental Health · doi:10.3109/09638230903469269 · Cited by 37
Bipolar II Disorder: An Overview of Recent Developments
Hadjipavlou, G. A., Mok, H., & Yatham, L. N. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404901203 · Cited by 38
“BD II and MDD patients receiving lamotrigine augmentation showed significantly greater improvement on their CGI scores, compared with placebo, but not on the Hamilton Depression Rating Scale (HDRS) or the Montgomery– Asberg Depression Rating Scale (MADRS) (33).”
BackgroundMethodInfluentialLamotrigine in patients with epilepsy and comorbid depressive symptoms
Fakhoury, T. A., Barry, J. J., Miller, J. M., Hammer, A. E., & Vuong, A. (2006) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2006.11.003 · Cited by 38
Is major depressive disorder a metabolic encephalopathy?
Harvey, B. H. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.946 · Cited by 36
“Supportive evidence for this, or as augmentation strategy, is increasing (Barbosa et al., 2003; Stryjer et al., 2003; Rogoz et al., 2004).”
BackgroundRubner, P., Koppi, S., & Conca, A. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902838242 · Cited by 39
“Even in treatment-resistant unipolar depression there is a tendency towards an early use of AEDs, especially lamotrigine (Barbee and Jamhour 2002; Barbosa et al. 2003; Hantouche et al. 2005; Manning et al. 2005).”
BackgroundLamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study
Gabriel, A. (2006) · Depression and Anxiety · doi:10.1002/da.20211 · Cited by 37
“Interest in lamotrigine’s possible efficacy in the treatment of mood disorders arose from epilepsy studies that described improved mood and quality of life unrelated to seizure control [Barbosa et al., 2003].”
BackgroundInfluentialWeisler, R. H., Cutler, A. J., Ballenger, J. C., Post, R. M., & Ketter, T. A. (2006) · CNS Spectrums · doi:10.1017/s1092852900014917 · Cited by 37
Lamotrigine Uses in Psychiatric Practice
Naguy, A., & Al-Enezi, N. (2017) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000535 · Cited by 35
Lamotrigine Reduces β-Site AβPP-Cleaving Enzyme 1 Protein Levels Through Induction of Autophagy
Wu, H., Lu, M., Wang, W., Zhang, M., Zhu, Q.-Q., Xia, Y., Xu, R., Yang, Y., Chen, L., & Ma, Q. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143162 · Cited by 33
“LTG also exhibits potential efficacy in the treatment of bipolar depression and resistant major depressive episodes [18–20].”
Antidepressant-Emergent Mood Switch in Korean Adolescents With Mood Disorder
Park, K. J., Shon, S., Lee, H.-J., Joo, Y., Youngstrom, E. A., & Kim, H. (2014) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000055 · Cited by 30
“7%) became hypomanic and was withdrawn from the trial.(50) There are also a few case reports of adults with recurrent depressive disorder who developed manic and hypomanic switch after adding lamotrigine(47,51) and a report of a severe manic switch in an adolescent with recurrent depressive disorder who had no family…”
BackgroundThe role of lamotrigine in the management of bipolar disorder
Ng, F., Hallam, K. T., Lucas, N., & Berk, M. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a920 · Cited by 43
“Another trial studied the adjunctive use of lamotrigine in treatment-resistant depression, including a subset with bipolar II depression (N = 8) although the majority had uni-polar depression (N = 15) (Barbosa et al 2003) (Table 3).”
Self-citationCharacterising de novo depression after epilepsy surgery
Wrench, J. M., Wilson, S. J., O’Shea, M. F., & Reutens, D. C. (2008) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.09.007 · Cited by 30
“More D D D E G G I K M N Q R R R R S S S W De novo depression after epilepsy surgery generally, lamotrigine is considered a mood stabilizer, and may be effective as an augmentation therapy for depression (Barbosa et al., 2003; Ettinger et al., 2006).”
Potentiation strategies for treatment‐resistant depression
Ros, S., Agüera, L., de la Gándara, J., Rojo, E., & de Pedro, J. M. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00676.x · Cited by 31
“In a doubleblind study of 15 unipolar patients plus eight bipolar patients in a depressive phase, no statistically significant differences were seen between lamotrigine + fluoxetine and fluoxetine + placebo in either pathology group (106).”
BackgroundIvković, M., Damjanović, A., Jovanović, A., Cvetić, T., & Jašović‐Gašić, M. (2009) · PubMed · Cited by 28
Presynaptic mechanisms of neuronal plasticity and their role in epilepsy
Meier, J. C., Semtner, M., Winkelmann, A., & Wolfart, J. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00164 · Cited by 31
“Interestingly, these drugs also have effects on psychiatric symptoms (Barbosa et al., 2003; Lexi-Comp, 2009; Andrus and Gilbert, 2010) indicating common underlying mechanisms of cognitive dysfunction and psychiatric symptoms of epilepsy.”
Zavodnick, A. D., & Ali, R. (2012) · Psychiatric Quarterly · doi:10.1007/s11126-012-9208-4 · Cited by 27
“[12] also suggested a role of lamotrigine for depression with comorbid anxiety.”
BackgroundLamotrigine in the treatment of bipolar disorder
Bhagwagar, Z., & Goodwin, G. M. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.8.1401 · Cited by 26
“2 Unipolar depression There are few trials examining the role of lamotrigine in the treatment of unipolar depression with far less impressive designs than those described above [43,44].”
BackgroundManaging inadequate antidepressant response in depressive illness
Haddad, P. M., Talbot, P. S., Anderson, I. M., & McAllister-Williams, H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv034 · Cited by 30
Askland, K. D., & PARSONS, M. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.02.024 · Cited by 29
“, 2002; Schou, 1979) and others to lamotrigine augmentation or monotherapy (Barbosa et al., 2003; Rocha and Hara, 2003; Barbee and Jamhour, 2002; Normann et al., 2002).”
BackgroundSchüle, C., Baghai, T. C., Eser, D., Nothdurfter, C., & Rupprecht, R. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701849978 · Cited by 24
“…Rocha and Hara 2003), openlabel studies (Gabriel 2006; Schindler and Anghelescu 2007), or case reports (Maltese 1999), as well as two small placebo-controlled trials (Normann et al. 2002; Barbosa et al. 2003) provide evidence for some antidepressant efficacy of lamotrigine in unipolar depression.”
BackgroundRecent Findings and Current Status of Augmentation Strategies
Nelson, J. C. (2007) · CNS Spectrums · doi:10.1017/s1092852900016011 · Cited by 23
Srichaiya, A., Longchoopol, C., Oo-puthinan, S., Sayasathid, J., Sripalakit, P., & Viyoch, J. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.10.018 · Cited by 21
Mohan, A., & Gundamaraju, R. (2014) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.147235 · Cited by 20
“treatment of epilepsy and bipolar disorder.[1] Chemically”
Lamotrigine (Lamictal IR) for the treatment of bipolar disorder
Bowden, C. L., & Singh, V. K. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.741590 · Cited by 20
“Lamotrigine plus paroxetine did not differ from paroxetine alone, although some individual HAM-D items, for example, depressed mood, guilt feelings, were significantly more improved in the adjunctive group [11] Lamotrigine plus fluoxetine did not differ significantly from fluoxetine plus placebo in a 6-week study on e…”
ResultLehnhoff, J., Strauß, U., Wierschke, S., Grosser, S., Pollali, E., Schneider, U. C., Holtkamp, M., Dehnicke, C., & Deisz, R. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.10.004 · Cited by 19
Epstein, I., Szpindel, I., & Katzman, M. A. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70003-4 · Cited by 23
Targeting Treatment-Resistant Depression
Mathys, M. L., & Mitchell, B. G. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011426972 · Cited by 22
Thán, M., Kocsis, P., Tihanyi, K., FODOR, L., Farkas, B. K., Kovács, G. L., Kis-Varga, Á., Szombathelyi, Z., & Tarnawa, I. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.12.008 · Cited by 17
Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
Won, E., Park, S., Han, K.-M., Sung, S.-H., Lee, H.-Y., Paik, J., Jeon, H. J., Lee, M., Shim, S.-H., Ko, Y., et al. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.4.468 · Cited by 19
“However, in those who did not respond to treatment previously, when a lamotrigine and fluoxetine augmentation group was compared to a lamotrigine monotherapy group, lamotrigine showed partial efficacy (82).”
ResultRational antidepressant selection: applying evidence-based medicine to complex real-world patients.
Zetin, M., Hoepner, C. T., & Bjornson, L. (2006) · PubMed · Cited by 17
Kumar, R., Nuñez, N. A., Prokop, L. J., Veldic, M., Betcher, H., & Singh, B. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001475 · Cited by 16
“Conversely, a small double-blind placebo-controlled trial of LAM (25–100 mg vs placebo) as an augmentation agent in resistant major depressive episodes (BD-II, n = 8, and MDD, n = 15) failed to reach statistical significance for the primary outcome (change in Hamilton Depression Rating Scale [HDRS]) between LAM and pl…”
BackgroundReimherr, F. W., Martin, M. L., Eudicone, J. M., Marchant, B. K., Tran, Q.-V., Pikalov, A., Marcus, R. N., Berman, R., & Carlson, B. X. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181db320f · Cited by 18
Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets
Panek, M., Kawalec, P., Malinowska‐Lipień, I., Brzostek, T., & Pilc, A. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1836160 · Cited by 17
Lamotrigine in Psychiatry: Pharmacology and Therapeutics
Jefferson, J. W. (2005) · CNS Spectrums · doi:10.1017/s1092852900010063 · Cited by 18
Shim, S., Mansari, M. E., & Blier, P. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203315 · Cited by 16
“Clinical studies have shown that lamotrigine has some beneficial antidepressant effects in major depressive episodes (Normann et al., 2002; Barbosa et al., 2003; Barbee et al., 2011), whereas currently there are no clinical studies for the use of carisbamate in mood disorders.”
BackgroundDiffusion of the new antiepileptic drug lamotrigine in Dutch clinical practice
Knoester, P. D., Belitser, S. V., Deckers, C. L. P., Keyser, A., Renier, W. O., Egberts, T. C. G., & Hekster, Y. A. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0839-8 · Cited by 14
“Trial data on the effectiveness of LTG in the treatment of diseases other than epilepsy have also started to emerge [23–26].”
BackgroundTherapeutic Armamentarium for Treating Depression
Howland, R. H. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2176 · Cited by 15
Phenytoin as an augmentation for SSRI failures: A small controlled study
Shapira, B., Nemets, B., Trachtenberg, A., & Belmaker, R. H. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.05.011 · Cited by 13
“Lamotrigine has been much more extensively studied in depression both as monotherapy and as an adjunct to SSRI therapy (Barbosa et al., 2003; Normann et al., 2002).”
Background
Metadata
- Authors
- Barbosa, L., Berk, M., & Vorster, M.
- Affiliations
- University of the Witwatersrand (ZA)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-04-15
- Volume
- 64
- Issue
- 4
- Pages
- 403-407
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2064478935
- Cited by
- 165
- References
- 0
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 9 · 2014: 11 · 2013: 6 · 2012: 11
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Deakin Research Online (Deakin University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- lamotrigine, fluoxetine, antidepressant augmentation, treatment-resistant depression, major depressive disorder, bipolar II disorder, antidepressant efficacy, Clinical Global Impression Scale, Hamilton Depression Rating Scale, Montgomery-Asberg Depression Rating Scale, small sample size limitations, responder analysis, dose titration, adverse events, drug discontinuation
- MeSH terms
- Lamotrigine, Adolescent, Adult, Aged, Anticonvulsants, Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Research Design, Severity of Illness Index, Triazines, Placebo Effect, Treatment Outcome, Outcome Assessment, Health Care, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.